INEX Seeks Approval to Spin-Out Assets Into Tekmira Pharmaceuticals
Inex Pharmaceuticals Corporation announced that it has filed with securities regulators in Canada and mailed to shareholders the information circular and proxy materials for the shareholders' meeting September 20, 2006 at which INEX will seek approval to spin-out the Company's technology, products, cash and partnerships into Tekmira Pharmaceuticals Corporation. The spin-out of Tekmira will take place by way of a Plan of Arrangement between INEX and its shareholders.
"We are confident that Tekmira will become a company with all the attributes necessary to take INEX's promising oligonucleotide-based products forward into clinical trials, to work with and benefit from the product development achievements of INEX's existing partners and to build significant value for shareholders," said Timothy M. Ruane, President and Chief Executive Officer of INEX.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.